Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — Investor Presentation (February 2015)
21 slides from Daiichi Sankyo's investor presentation, Feb 17, 2015
Slide 1: SAVAYSA (edoxaban) U.S. Opportunity
SAVAYSA™ (edoxaban) U.S. Opportunity February 17, 2015 Ken Keller President, U.S. Commercial DSI, Inc.
Slide 2: Key Discussion Points
Key Discussion Points • Daiichi Sankyo, Inc. (DSI) in the U.S. • SAVAYSA™ (edoxaban) U.S. Indication • NOAC Market Opportunity and Dynamics • SAVAYSA’s Unique Benefits • Key Success Factors • Expectations 2
Slide 3: Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc. Daiichi Sankyo, Inc., headquartered in Parsippany, NJ, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd. Daiichi Sankyo, Inc. is a member of the Daiichi Sankyo Group. • $1.7 billion net sales FY 2013 in the U.S. • 2,500 total employees in U.S. (approximate) 3
Slide 4: DSI Has Built a Strong Portfolio in the U.S.
DSI Has Built a Strong Portfolio in the U.S. We Have a History of Competing Intensely and Winning in Highly Competitive Markets FY06 – FY13 DSI Net Revenue USD, Millions 1,722 1,719 1,614 1,530 1,435 1,267 1,126 946 Other* Cevimeline Franchise (incl AG) EFFIENT Co-Promotion Revenue WELCHOL BENICAR /
Slide 5: Approved in the U.S. on January 8, 2015
Approved in the U.S. on January 8, 2015 Factor Xa Inhibitor 60, 30, 15 mg tablets Once-daily dosing *Please see Important Safety Information ( www.savaysa.com ) 5
Slide 6: Atrial Fibrillation Affects 6.1 MM Americans, DVT/PE Close to 1 MM
Atrial Fibrillation Affects 6.1 MM Americans, DVT/PE Close to 1 MM • NVAF increases the risk of stroke five-fold • DVT and PE patients are at high risk for recurrence • For 60 years, a vitamin K antagonist (warfarin) was the only oral anti-coagulant option • Highly effective – reduces stroke/SE by 6
Slide 7: SAVAYSA Demonstrated Significantly Less Major Bleeding and was Non-inferior to Warfarin
SAVAYSA Demonstrated Significantly Less Major Bleeding and was Non-inferior to Warfarin in Stroke/SEE SAVAYSA 60 MG Including patients dose-reduced to 30 mg 21,105 Warfarin NVAF Patients Dose-adjusted to maintain a target INR of 2.0 to 3.0 enrolled Edoxaban 30 mg Including patients dose-reduced to 1
Slide 8: SAVAYSA Safety Profile Compared to Warfarin Maintained in CrCL ≤95 mL/min
SAVAYSA Safety Profile Compared to Warfarin Maintained in the CrCL ≤95 mL/min Patient Population SAVAYSA Patients Had Significantly Less Major Bleeding, Similar to Overall Population Event SAVAYSA Warfarin SAVAYSA ENGAGE AF-TIMI 48 60 mg (N=5485) 60 mg vs Warfarin Major Bleeding Events in CrCL ≤95 m
Slide 9: SAVAYSA Reduced Risk of Stroke/SEE in CrCL ≤95 mL/min Population
SAVAYSA Reduced Risk of Stroke/SEE in the CrCL ≤95 mL/min Patient Population ENGAGE AF-TIMI 48 ENGAGE AF-TIMI 48 Non-inferiority for Stroke/SEE Stroke/SEE in CrCL ≤95 mL/min in Overall Population 2.0% 2.0% 1.8% Warfarin (N=7012) Warfarin (N=5485) (N=211) 1.5% SAVAYSA 60 mg (N=7012) SAVAYSA 60 mg (N=
Slide 10: SAVAYSA Approval Supports a Unique, Compelling and Differentiating Profile
SAVAYSA Approval in the U.S. Supports a Unique, Compelling and Differentiating Profile For NVAF Patients with CrCL ≤95 mL/min compared to warfarin Lower Major Bleeds HR (95% CI): 0.84 (0.73-0.97) Lower Intracranial Hemorrhage HR (95% CI): 0.44 (0.32-0.61) Lower Fatal Bleeds HR (95% CI): 0.51 (0.30-0
Slide 11: NOAC Market Large and Accelerating
NOAC Market Large and Accelerating The Market is Expected to Exceed $8B in Net Sales by 2020 2011 – 2020 NOAC Market Net Sales Projections – US USD, Millions 9,000 $8,452 $7,956 8,000 $7,419 $6,807 7,000 $6,012 6,000 SAVAYSA $4,879 5,000 Eliquis $3,389 4,000 Xarelto 3,000 Pradaxa $2,013 2,000 $1,121
Slide 12: SAVAYSA Opportunity is Driven by NVAF
SAVAYSA Opportunity is Driven by NVAF 82% of NOAC-Treated Patients Have NVAF 2014 U.S. NOAC-Treated Patients 1.6 Million VTE 0.3M 18% NVAF 1.3M 82% Source: Internal Analysis Based on Decision Resources, Symphony Health Solutions 12
Slide 13: Nearly a Third of NVAF and a Quarter of VTE Patients Treated with NOACs
Nearly a Third of NVAF and a Quarter of VTE Patients are Treated with NOACs, Indicating Significant Opportunity for Expansion 2014 U.S. NVAF Drug-Treated 2014 U.S. VTE Drug-Treated Patients 4.14 Million Patients 1.1 Million Other Other 0.11M 0.79 M NOAC 10% NOAC 19% 1.29M 0.28M 31% 25% Warfarin Warf
Slide 14: NOACs Remain Significantly Under-Penetrated
NOACs Remain Significantly Under-Penetrated New Patient Market Share %, NBRx 90% 80% 70% 60% 50% Warfarin 40% Xarelto® 30% 20% Eliquis® 10% Pradaxa® 0% Source: Symphony Health Solutions PHAST 2.0 14
Slide 15: Physicians Select NOACs Based on a Few Key Benefits
Market Research: Physicians Select NOACs Based on a Few Key Benefits NOAC Use Drivers Efficacy Strongest Safety Driver Availability of Reversal Agent Rate of CV-related Death Additional Indications or Label Inclusions Dosing Frequency Special Limitations/Warning Relative Coverage (Similar, Above, Be
Slide 16: SAVAYSA Key Market Success Factors
SAVAYSA Key Market Success Factors • Position the unique and compelling clinical profile of SAVAYSA as the drug of choice for appropriate patients • Establish access and reimbursement • Compete effectively • Leverage our existing relationships with prescribers in the cardiovascular space 16
Slide 17: NOAC Pricing
NOAC Pricing SAVAYSA List Price / Day is 12% Less Than Other NOACs U.S. List Price / Day $11.00 $10.49 $10.49 $10.50 $10.00 $9.24 $9.00 NOAC $8.00 $7.00 $6.00 $5.00 Warfarin Pradaxa Xarelto Eliquis SAVAYSA Feb 2015 $10.49 $10.49 $10.50 $9.24 WAC Price Source: First Data Bank (February 2015). List pr
Slide 18: Benicar Launched as the 7th Brand in the ARB Class
DSI Has a History of Success Entering Competitive Markets - Benicar Launched as the 7th Brand in The ARB Class Cozaar® losartan ARB Class, U.S. New Prescriptions Market Share Diovan® valsartan % NRx Avapro® irbesartan 70% Atacand® candesartan Micardis® telmisartan 60% Teveten® eprosartan 50% BENICAR
Slide 19: The DSI Sales Team is Competitively Tested and Highly Effective
The DSI Sales Team is Competitively Tested and Highly Effective Physicians Consistently Assign High Performance Ratings to Our Sales Team Physician Perceptions of DSI Sales Reps Overall Relationship Disease Knowledge Product Knowledge Better than competitor Same as competitor Worse
Slide 20: We Are Confident
We Are Confident SAVAYSA Will Become a Successful and Valuable Drug in the U.S. Market 1. Large, growing and under-penetrated market 2. We understand the customers 3. SAVAYSA unique benefits are motivating • Lower major bleeding vs. warfarin • Reduced stroke/SEE vs. warfarin • Once daily dosing 4. S
Slide 21: Contact address regarding this material
Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Financial forecasts, future projections and R&D information that Daiichi Sankyo discloses may include information that might be classified as “Forward Looking Statement”. These f
Daiichi Sankyo Company — Investor Presentation (February 2015) on 6ix